Cross-lineage protection between chikv primary infection and mayv secondary exposure in mice (2023)
- Authors:
- USP affiliated authors: DURIGON, EDISON LUIZ - ICB ; MACHADO, RAFAEL RAHAL GUARAGNA - ICB
- Unidade: ICB
- DOI: 10.1016/j.ijid.2023.04.044
- Subjects: MICROBIOLOGIA; DOENÇAS INFECCIOSAS; CAMUNDONGOS; MODELOS ANIMAIS DE DOENÇAS; INTERFERONS; ANTICORPOS; FENÓTIPOS; CITOCINAS; LINHAGENS ANIMAIS; INFLAMAÇÃO; QUIMIOCINAS; VIROSES EM ANIMAIS
- Language: Inglês
- Imprenta:
- Publisher: Elsevier Ltd.
- Publisher place: Oxford
- Date published: 2023
- Source:
- Título: International Journal of Infectious Diseases
- ISSN: 1878-3511
- Volume/Número/Paginação/Ano: v. 130, Supl. 2, p. S18, 2023
- Conference titles: International Congress on Infectious Diseases
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
- Cor do Acesso Aberto: closed
-
ABNT
MACHADO, R. Rahal Guaragna et al. Cross-lineage protection between chikv primary infection and mayv secondary exposure in mice. International Journal of Infectious Diseases, v. 130, p. S18, 2023Tradução . . Disponível em: https://doi.org/10.1016/j.ijid.2023.04.044. Acesso em: 27 dez. 2025. -
APA
Machado, R. R. G., Rafael, G. H., Scharton, D., Campos, R. K., Liang, Y., Plante, K. S., et al. (2023). Cross-lineage protection between chikv primary infection and mayv secondary exposure in mice. International Journal of Infectious Diseases, 130, S18. doi:10.1016/j.ijid.2023.04.044 -
NLM
Machado RRG, Rafael GH, Scharton D, Campos RK, Liang Y, Plante KS, Weaver SC, Durigon EL. Cross-lineage protection between chikv primary infection and mayv secondary exposure in mice [Internet]. International Journal of Infectious Diseases. 2023 ; 130 S18.[citado 2025 dez. 27 ] Available from: https://doi.org/10.1016/j.ijid.2023.04.044 -
Vancouver
Machado RRG, Rafael GH, Scharton D, Campos RK, Liang Y, Plante KS, Weaver SC, Durigon EL. Cross-lineage protection between chikv primary infection and mayv secondary exposure in mice [Internet]. International Journal of Infectious Diseases. 2023 ; 130 S18.[citado 2025 dez. 27 ] Available from: https://doi.org/10.1016/j.ijid.2023.04.044 - Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial
- Anti‐A and SARS‐CoV‐2: an intriguing association
- Nebulized enriched heparin improves respiratory parameters in patients with COVID-19: a phase I/II randomized and triple-blind clinical trial
- A longitudinal study of convalescent plasma (CCP) donors and correlation of ABO group, initial neutralizing antibodies (nAb), and body mass index (BMI) with nAb and anti‐nucleocapsid (NP) SARS‐CoV‐2 antibody kinetics: proposals for better quality of CCP collections
- Nebulized enriched heparin to treat no critical patients with Sars-Cov-2: triple-blind clinical trial
- Surrogate test performance for SARS-CoV-2 neutralizing antibodies (nAbs) for convalescent plasma (CCP): how useful could they be?
- Soroprevalência da infecção pelos vírus Zika (ZIKV) e Dengue (DENV) em parturientes e transferência transplacentária de anticorpos anti-ZIKV e anti- DENV em neonatos na cidade de São Paulo, Brasil
- Correlation between SARS‐COV‐2 antibody screening by immunoassay and neutralizing antibody testing
- Neonatal consequences of maternal exposure to the chikungunya virus
- UV-C (254 nm) lethal doses for SARS-CoV-2
Informações sobre o DOI: 10.1016/j.ijid.2023.04.044 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
